No abstract available
Keywords:
Oritavancin; Staphylococcus aureus; bacteremia; immunosuppressed patient; skin and soft tissues.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Glycopeptides / therapeutic use
-
Humans
-
Lipoglycopeptides / therapeutic use
-
Methicillin-Resistant Staphylococcus aureus*
-
Neoplasms* / drug therapy
-
Soft Tissue Infections* / complications
-
Soft Tissue Infections* / drug therapy
-
Staphylococcal Infections* / drug therapy
-
Staphylococcus aureus
Substances
-
oritavancin
-
Lipoglycopeptides
-
Anti-Bacterial Agents
-
Glycopeptides